M&As this week: Savara Pharma, Xiangxue Pharmaceuticals
Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.
Savara Pharmaceuticals plans to expand its pipeline of orphan respiratory drugs by acquiring Serendex Pharmaceuticals, a provider of inhalation therapies for rare respiratory conditions.
Pursuant to the transaction, Savara Pharma will acquire all of Serendex Pharma’s assets to add up to two new programmes in its pipeline.
Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.
